

Global Generic Oncology Drugs Market Report and Forecast 2023-2031

Market Report | 2023-05-06 | 160 pages | EMR Inc.

AVAILABLE LICENSES:

- Single User License \$5999.00
- Five User License \$7999.00
- Corporate License \$9999.00

Report description:

Global Generic Oncology Drugs Market Report and Forecast 2023-2031

Global Generic Oncology Drugs Market Outlook

The global generic oncology drugs market value was USD 25.3 billion in 2022, driven by the increasing prevalence of cancer across the globe. The market size is anticipated to grow at a CAGR of 6.2% during the forecast period of 2023-2031 to achieve a value of USD 43.7 billion by 2031.

Generic Oncology Drugs Introduction

Generic Oncology Drugs refer to the pharmaceuticals that are used to prevent, diagnose, and treat various types of cancer. These drugs are generally produced after the patent expiration of their branded counterparts, making them more affordable for patients. The global generic oncology drugs market is witnessing significant growth due to the rising prevalence of cancer worldwide and increasing demand for cost-effective treatments. Additionally, the introduction of biosimilars in the oncology drug market is expected to drive market growth in the coming years.

However, the high cost of research and development activities and the stringent regulatory policies regarding drug approval are the major factors that may hamper the growth of the market. In addition, the limited availability of oncology drugs in underdeveloped and developing countries may also restrain market growth.

Despite these challenges, the market is expected to grow significantly due to the increasing focus of key players on developing generic versions of cancer drugs and the rising demand for personalized medicine in cancer treatment. The emergence of new technologies such as precision medicine and immunotherapy is also expected to boost the market growth in the coming years.

Generic Oncology Drugs Market Scenario

Generic oncology drugs are low-cost alternatives to their brand-name counterparts, designed to treat cancer. These drugs are equivalent in terms of dosage, strength, route of administration, quality, and intended use as the innovator drugs but are sold at lower prices. These drugs are widely available in various formulations, including injectables, capsules, tablets, and liquids.

The global generic oncology drugs market is driven by factors such as increasing prevalence of cancer, patent expiry of blockbuster drugs, and rising demand for cost-effective treatment options. In addition, the advent of new technologies in drug delivery and the increasing trend of mergers and acquisitions among key players in the market are expected to create growth.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

opportunities.

However, the stringent regulatory requirements for approval and quality control of generic drugs and the high cost of research and development of new drugs are some of the major factors that may restrain the growth of the global generic oncology drugs market.

Overall, the global generic oncology drugs market is projected to exhibit significant growth in the coming years, driven by increasing demand for cost-effective cancer treatment options, rising research and development activities, and increasing adoption of advanced technologies.

Generic Oncology Drugs Market Segmentations

Market Breakup by Molecule Type

- Large Molecule
- Small Molecule

Market Breakup by Route of Administration

- Oral
- Parentals

Market Breakup by Distribution Channel

- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy

Market Breakup by Region

- North America
- United States of America
- Canada

- Europe
- United Kingdom
- Germany
- France
- Italy
- Others

- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- Others

- Latin America
- Brazil
- Argentina
- Mexico
- Others

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others

Key Trends in the Generic Oncology Drugs Market

Some key trends in the generic oncology drugs market are:

- Increasing prevalence of cancer: As the incidence of cancer continues to rise globally, the demand for effective and affordable treatment options is also increasing. This is driving the growth of the generic oncology drugs market.
- Growing focus on cost containment: With rising healthcare costs, payers and providers are increasingly focused on cost containment measures. Generic drugs offer a more cost-effective alternative to branded drugs, which is driving the growth of the generic oncology drugs market.
- Patent expirations of branded drugs: The patent expirations of several blockbuster oncology drugs are leading to the entry of generic versions of these drugs. This is creating opportunities for generic drug manufacturers to enter the market and gain market share.
- Increasing competition among generic drug manufacturers: As more players enter the market, competition among generic drug manufacturers is increasing. This is leading to price erosion, which is a major challenge for companies operating in this market.
- Growing demand for biosimilars: Biosimilars are gaining traction in the oncology market, as they offer a more affordable alternative to expensive biologics. This is driving the growth of the generic oncology drugs market.

Generic Oncology Drugs Market: Competitor Landscape

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

- Novartis AG
- Pfizer Inc.
- GlaxoSmithKline plc
- Teva Pharmaceutical Industries Ltd.
- Merk & Company, Inc.
- Aurobindo Pharma.
- Hikma Pharmaceuticals PLC
- Mylan N.V.
- NATCO Pharma Limited
- CELGENE CORPORATION

Table of Contents:

- 1 Preface
 - 1.1 Objectives of the Study
 - 1.2 Key Assumptions
 - 1.3 Report Coverage - Key Segmentation and Scope

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 1.4 Research Methodology
- 2 Executive Summary
- 3 Cancer Overview
 - 3.1 Guidelines and Stages
 - 3.2 Pathophysiology
 - 3.3 Screening and Diagnosis
 - 3.4 Treatment Pathway
- 4 Patient Profile
 - 4.1 Patient Profile Overview
 - 4.2 Patient Psychology and Emotional Impact Factors
 - 4.3 Risk Assessment and Treatment Success Rate
- 5 Cancer Epidemiology Analysis
 - 5.1 Epidemiology Overview (2016-2031)
 - 5.2 North America Cancer Epidemiology (2016-2031)
 - 5.3 Europe Cancer Epidemiology (2016-2031)
 - 5.4 Asia-Pacific Cancer Epidemiology (2016-2031)
 - 5.5 Latin America Cancer Epidemiology (2016-2031)
 - 5.6 Middle East & Africa Cancer Epidemiology (2016-2031)
- 6 Global Generic Oncology Drugs Market Overview
 - 6.1 Global Generic Oncology Drugs Market Historical Value (2016-2022)
 - 6.2 Global Generic Oncology Drugs Market Forecast Value (2023-2031)
- 7 Global Generic Oncology Drugs Market Landscape
 - 7.1 Global Generic Oncology Drugs Landscape
 - 7.1.1 Analysis by Year of Establishment
 - 7.1.2 Analysis by Company Size
 - 7.1.3 Analysis by Region
 - 7.2 Global Generic Oncology Drugs Product Landscape
 - 7.2.1 Analysis by Molecule
 - 7.2.2 Analysis by Route of Administration
 - 7.2.3 Analysis by Distribution Channel
- 8 Generic Oncology Drug Challenges and Unmet Needs
 - 8.1 Treatment Pathway Challenges
 - 8.2 Compliance and Drop-Out Analysis
 - 8.3 Awareness and Prevention Gaps
- 9 Cost of Treatment
- 10 Global Generic Oncology Drugs Market Dynamics
 - 10.1 Market Drivers and Constraints
 - 10.2 SWOT Analysis
 - 10.3 Porter's Five Forces Model
 - 10.4 Key Demand Indicators
 - 10.5 Key Price Indicators
 - 10.6 Industry Events, Initiatives, and Trends
 - 10.7 Value Chain Analysis
- 11 Global Generic Oncology Drugs Market Segmentation
 - 11.1 Global Generic Oncology Drugs Market by Molecule Type
 - 11.1.1 Market Overview
 - 11.1.2 Large Molecule

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.1.3 Small Molecule
- 11.2 Global Generic Oncology Drugs Market by Route of Administration
 - 11.2.1 Market Overview
 - 11.2.2 Oral
 - 11.2.3 Parentals
- 11.3 Global Generic Oncology Drugs Market by Distribution Channel
 - 11.3.1 Market Overview
 - 11.3.2 Hospital Pharmacy
 - 11.3.3 Online Pharmacy
 - 11.3.4 Retail Pharmacy
- 11.4 Global Generic Oncology Drugs Market by Region
 - 11.4.1 Market Overview
 - 11.4.2 North America
 - 11.4.3 Europe
 - 11.4.4 Asia Pacific
 - 11.4.5 Latin America
 - 11.4.6 Middle East and Africa
- 12 North America Generic Oncology Drugs Market
 - 12.1 Market Share by Country
 - 12.2 United States of America
 - 12.3 Canada
- 13 Europe Generic Oncology Drugs Market
 - 13.1 Market Share by Country
 - 13.2 United Kingdom
 - 13.3 Germany
 - 13.4 France
 - 13.5 Italy
 - 13.6 Others
- 14 Asia Pacific Generic Oncology Drugs Market
 - 14.1 Market Share by Country
 - 14.2 China
 - 14.3 Japan
 - 14.4 India
 - 14.5 ASEAN
 - 14.6 Australia
 - 14.7 Others
- 15 Latin America Generic Oncology Drugs Market
 - 15.1 Market Share by Country
 - 15.2 Brazil
 - 15.3 Argentina
 - 15.4 Mexico
 - 15.5 Others
- 16 Middle East and Africa Generic Oncology Drugs Market
 - 16.1 Market Share by Country
 - 16.2 Saudi Arabia
 - 16.3 United Arab Emirates
 - 16.4 Nigeria

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 16.5 South Africa
- 16.6 Others
- 17 Patent Analysis
 - 17.1 Analysis by Type of Patent
 - 17.2 Analysis by Publication year
 - 17.3 Analysis by Issuing Authority
 - 17.4 Analysis by Patent Age
 - 17.5 Analysis by CPC Analysis
 - 17.6 Analysis by Patent Valuation
 - 17.7 Analysis by Key Players
- 18 Grants Analysis
 - 18.1 Analysis by year
 - 18.2 Analysis by Amount Awarded
 - 18.3 Analysis by Issuing Authority
 - 18.4 Analysis by Grant Application
 - 18.5 Analysis by Funding Institute
 - 18.6 Analysis by NIH Departments
 - 18.7 Analysis by Recipient Organization
- 19 Clinical Trials Analysis
 - 19.1 Analysis by Trial Registration Year
 - 19.2 Analysis by Trial Status
 - 19.3 Analysis by Trial Phase
 - 19.4 Analysis by Therapeutic Area
 - 19.5 Analysis by Geography
- 20 Funding Analysis
 - 20.1 Analysis by Funding Instances
 - 20.2 Analysis by Type of Funding
 - 20.3 Analysis by Funding Amount
 - 20.4 Analysis by Leading Players
 - 20.5 Analysis by Leading Investors
 - 20.6 Analysis by Geography
- 21 Partnership and Collaborations Analysis
 - 21.1 Analysis by Partnership Instances
 - 21.2 Analysis by Type of Partnership
 - 21.3 Analysis by Leading Players
 - 21.4 Analysis by Geography
- 22 Regulatory Framework
 - 22.1 Regulatory Overview
 - 22.1.1 US FDA
 - 22.1.2 EU EMA
 - 22.1.3 INDIA CDSCO
 - 22.1.4 JAPAN PMDA
 - 22.1.5 Others
- 23 Supplier Landscape
 - 23.1 Novartis AG
 - 23.1.1 Financial Analysis
 - 23.1.2 Product Portfolio

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 23.1.3 Demographic Reach and Achievements
- 23.1.4 Mergers and Acquisitions
- 23.1.5 Certifications
- 23.2 Pfizer Inc.
 - 23.2.1 Financial Analysis
 - 23.2.2 Product Portfolio
 - 23.2.3 Demographic Reach and Achievements
 - 23.2.4 Mergers and Acquisitions
 - 23.2.5 Certifications
- 23.3 GlaxoSmithKline plc
 - 23.3.1 Financial Analysis
 - 23.3.2 Product Portfolio
 - 23.3.3 Demographic Reach and Achievements
 - 23.3.4 Mergers and Acquisitions
 - 23.3.5 Certifications
- 23.4 Teva Pharmaceutical Industries Ltd.
 - 23.4.1 Financial Analysis
 - 23.4.2 Product Portfolio
 - 23.4.3 Demographic Reach and Achievements
 - 23.4.4 Mergers and Acquisitions
 - 23.4.5 Certifications
- 23.5 Merk & Company, Inc.
 - 23.5.1 Financial Analysis
 - 23.5.2 Product Portfolio
 - 23.5.3 Demographic Reach and Achievements
 - 23.5.4 Mergers and Acquisitions
 - 23.5.5 Certifications
- 23.6 Aurobindo Pharma.
 - 23.6.1 Financial Analysis
 - 23.6.2 Product Portfolio
 - 23.6.3 Demographic Reach and Achievements
 - 23.6.4 Mergers and Acquisitions
 - 23.6.5 Certifications
- 23.7 Hikma Pharmaceuticals PLC
 - 23.7.1 Financial Analysis
 - 23.7.2 Product Portfolio
 - 23.7.3 Demographic Reach and Achievements
 - 23.7.4 Mergers and Acquisitions
 - 23.7.5 Certifications
- 23.8 Mylan N.V.
 - 23.8.1 Financial Analysis
 - 23.8.2 Product Portfolio
 - 23.8.3 Demographic Reach and Achievements
 - 23.8.4 Mergers and Acquisitions
 - 23.8.5 Certifications
- 23.9 NATCO Pharma Limited
 - 23.9.1 Financial Analysis

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 23.9.2 Product Portfolio
- 23.9.3 Demographic Reach and Achievements
- 23.9.4 Mergers and Acquisitions
- 23.9.5 Certifications
- 23.10 CELGENE CORPORATION
 - 23.10.1 Financial Analysis
 - 23.10.2 Product Portfolio
 - 23.10.3 Demographic Reach and Achievements
 - 23.10.4 Mergers and Acquisitions
 - 23.10.5 Certifications
- 24 Global Generic Oncology Drugs Market - Distribution Model (Additional Insight)
 - 24.1 Overview
 - 24.2 Potential Distributors
 - 24.3 Key Parameters for Distribution Partner Assessment
- 25 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 26 Company Competitiveness Analysis (Additional Insight)
 - 26.1 Very Small Companies
 - 26.2 Small Companies
 - 26.3 Mid-Sized Companies
 - 26.4 Large Companies
 - 26.5 Very Large Companies
- 27 Payment Methods (Additional Insight)
 - 27.1 Government Funded
 - 27.2 Private Insurance
 - 27.3 Out-of-Pocket

Global Generic Oncology Drugs Market Report and Forecast 2023-2031

Market Report | 2023-05-06 | 160 pages | EMR Inc.

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$5999.00
	Five User License	\$7999.00
	Corporate License	\$9999.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

☐ ** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-05-02"/>
		Signature	<input type="text"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com